MYOK News and Press, MyoKardia Inc. From 06/18/19

SOUTH SAN FRANCISCO, Calif., June 18, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today announced that Jake Bauer, Chief Business Officer, w...

First-in-Human Data for MYK-491 in Healthy Volunteers Demonstrated Well-Tolerated Increases in Cardiac Contractility Topline Results from Phase 2a Clinical Trial of MYK-491 in Patients with Stable Heart Failure with Reduced Ejection Fraction Anticipated in Second Half 2019 SOUTH SA...

MyoKardia, Inc. (MYOK) Q1 2019 Earnings Conference Call May 09, 2019 04:30 PM ET Company Participants Michelle Corral - Senior Director of Corporate Communications and Investor Relations Tassos Gianakakos - President and Chief Executive Officer Jay Edelberg - Senior Vice Presiden...

MyoKardia (NASDAQ: MYOK ): Q1 GAAP EPS of -$0.93 misses by $0.24 . More news on: MyoKardia, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Announces Enrollment Completing in the Phase 2 MAVERICK-HCM Trial Company to Host Conference Call and Webcast Today at 4:30 p.m. ET (1:30 p.m. PT) SOUTH SAN FRANCISCO, Calif., May 09, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical compan...

SOUTH SAN FRANCISCO, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Off...

SOUTH SAN FRANCISCO, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- MyoKardia, a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of serious cardiovascular diseases, today announced the award of $750,000 divided among three innovative research projects thro...

SOUTH SAN FRANCISCO, Calif., May 02, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today announced that it will report first quarter 2019 fina...

Mavacamten is Being Developed to Treat the Most Common Inherited Form of Heart Disease, Hypertrophic Cardiomyopathy, for Which No Targeted Medical Therapies Exist Twelve-Week Treatment with Mavacamten Demonstrated Reductions in Obstruction and Improvements in Patient Symptoms and Func...

MyoKardia ( MYOK -0.9% ) announced the pricing of an underwritten public offering of 4.93M shares of its common stock at a price of $51/share. More news on: MyoKardia, Inc., Read more ...